Saram ConsultingGxP & AI Consulting for Life Sciences. Custom AI integrations, Part 11 compliance validation, and equity-based engineering partnerships for biotech.Explore Services at saram.io →
← Back to Home

Vor Bio

NASDAQ: VOR ↗$19.82 USD~$1.2B MCAP

Clinical-stage biopharmaceutical company developing therapies for autoantibody-driven autoimmune disease. Its lead program, telitacicept, is a dual BAFF/APRIL inhibitor licensed from RemeGen and is in Phase 3 development for generalized myasthenia gravis and Sjogren's disease.

Company Info

Sector:Autoimmune Disease / Biologics
Headquarters:Cambridge, Massachusetts, United States
Founded:2015

Clinical Development Pipeline

telitacicept

Target: BAFF / APRIL
Generalized myasthenia gravis
Preclinical
Phase 1
Phase 2
Phase 3
Approved

telitacicept

Target: BAFF / APRIL
Sjogren's disease
Preclinical
Phase 1
Phase 2
Phase 3
Approved

RC298

Target: BAFF / APRIL
Undisclosed autoimmune indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

Leadership Team

Jean-Paul Kress, MD

Chief Executive Officer and Chairman of the Board

Careers & Job Openings

See all open roles

Multiple Departments
Cambridge, MA
Apply Now →